INSILICO DISCOVERY OF HUMAN AURORA B KINASE INHIBITORS BY MOLECULAR DOCKING, PHARMACOPHORE VALIDATION AND ADMET STUDIES

  • Rajashekar Vadlakonda Vikas College of Pharmacy, Kakatiya university
  • Sreenivas Enaganti
  • Raghunandan Nerella

Abstract

Objectives: To predict the anticancer potentiality of some newly designed azaindole derivatives gainst human Aurora B kinase and to identify the critical features important for their activity.

Methods: Initially, the derivatives of azaindoles, (Z)-2-(oxo-1 H-pyrrolo [2,3-b] pyridine-3 (2H)-ylidene)-N-(p-substituted) hydrazine carbothioamide (scaffold A), (E)-3-((E)-substituted benzylidene hydrazono)-1H-pyrrolo[2,3-b]pyridine-2(3H)-one (scaffold B), and 1-(2-substituted acetyl)-1H- pyrrolo [2,3-b]pyridine-2,3-dione are synthesized and sketched using ACD/ChemSketch (12.0). With the 3D converted compounds, docking into the active site of the retrieved protein Aurora B kinase is carried out using LibDock module of discovery studio (DS). Further absorption, distribution, metabolism, excretion and toxicity (ADMET) properties, ligand, and structure-based pharmacophore modeling are applied using DS.

Results: Through docking and pharmacophore studies, it is revealed that compound C13 (N-{(Z)-2-[4-(dimethylamino)phenyl]ethenyl}-1H- pyrrolo[2,3-b]pyridine-3-carboxamide) shows the highest binding affinity and good pharmacophoric features with acceptable fit values of both ligand and structure-based pharmacophore models. Furthermore, the calculated ADMET properties are reliable.

Conclusion: These studies suggest that the compound C13 (N-{(Z)-2-[4-(dimethylamino)phenyl]ethenyl}-1H-pyrrolo[2,3-b]pyridine-3-carboxamide)

may act as a potent target in the anticancer therapy.

Keywords: Aneuploidy, Aurora B kinase, Azaindole, Cancer, Cell cycle, Genome stability.

 

Author Biography

Rajashekar Vadlakonda, Vikas College of Pharmacy, Kakatiya university
Pharmaceutical chemistry

References

1. Andrews PD. Aurora kinases: Shining lights on the therapeutic horizon?
Oncogene 2005;24(32):5005-15.
2. Bolanos-Garcia VM. Aurora kinases. Int J Biochem Cell Biol
2005;37(8):1572-7.
3. Katayama H, Sen S. Aurora kinase inhibitors as anticancer molecules.
Biochim Biophys Acta 2010;1799(10-12):829-39.
4. Hochegger H, Hégarat N, Pereira-Leal JB. Aurora at the pole and equator: Overlapping functions of Aurora kinases in the mitotic spindle.
6. Lens SM, Voest EE, Medema RH. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer
2010;10(12):825-41.
7. Bischoff JR, Plowman GD. The Aurora/Ipl1p kinase family: Regulators of chromosome segregation and cytokinesis. Trends Cell Biol 1999;9(11):454-9.
8. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5(1):1-10.
9. Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 2004;14(1):29-36.
10. Ke YW, Dou Z, Zhang J, Yao XB. Function and regulation of Aurora/ Ipl1p kinase family in cell division. Cell Res 2003;13(2):69-81.
11. Jayanthan A, Ruan Y, Truong TH, Narendran A. Aurora kinases as druggable targets in pediatric leukemia: Heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents. PLoS One 2014;9(1):e102741.
12. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat
Rev Cancer 2004;4(1):927-36.
13. Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: Conducting cell division. Nat Rev Mol Cell Biol 2007;8(10):798-812.
14. Kelly AE, Funabiki H. Correcting aberrant kinetochore microtubule attachments: An Aurora B-centric view. Curr Opin Cell Biol
2009;21(1):51-8.
15. van der Waal MS, Hengeveld RC, van der Horst A, Lens SM. Cell division control by the Chromosomal Passenger Complex. Exp Cell Res 2012;318(12):1407-20.
16. Cooke CA, Heck MM, Earnshaw WC. The inner centromere protein (INCENP) antigens: Movement from inner centromere to midbody during mitosis. J Cell Biol 1987;105:2053-67.
17. Earnshaw WC, Bernat RL. Chromosomal passengers: Toward an integrated view of mitosis. Chromosoma 1991;100(3):139-46.
18. Earnshaw WC, Cooke CA. Analysis of the distribution of the INCENPs throughout mitosis reveals the existence of a pathway of structural changes in the chromosomes during metaphase and early events in cleavage furrow formation. J Cell Sci 1991;98:443-61.
19. Adams RR, Maiato H, Earnshaw WC, Carmena M. Essential roles of Drosophila inner centromere protein (INCENP) and aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation. J Cell Biol
2001;153(4):865-80.
20. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP.
Survivin is required for stable checkpoint activation in taxol-treated
HeLa cells. J Cell Sci 2003;116:2987-98.
21. Honda R, Körner R, Nigg EA. Exploring the functional interactions
between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell
2003;14(8):3325-41.
22. Gassmann R, Carvalho A, Henzing AJ, Ruchaud S, Hudson DF, Honda R, et al. Borealin: A novel chromosomal passenger required for stability of the bipolar mitotic spindle. J Cell Biol 2004;166(2):179-91.
23. Vader G, Kauw JJ, Medema RH, Lens SM. Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep 2006;7(1):85-92.
24. Bayliss R, Fry A, Haq T, Yeoh S. On the molecular mechanisms of mitotic kinase activation. Open Biol 2012;2(11):120136.
Statistics
310 Views | 387 Downloads
How to Cite
Vadlakonda, R., S. Enaganti, and R. Nerella. “INSILICO DISCOVERY OF HUMAN AURORA B KINASE INHIBITORS BY MOLECULAR DOCKING, PHARMACOPHORE VALIDATION AND ADMET STUDIES”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 2, Feb. 2017, pp. 165-74, doi:10.22159/ajpcr.2017.v10i2.14974.
Section
Original Article(s)